An observational study in Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer and EGFR Gene Mutation, sponsored by Hellenic Cooperative Oncology Group. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-23.
Sponsored by Hellenic Cooperative Oncology Group · Observational
This is an observational, non-interventional, single-country, multi center, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC) who had been treated with Afatinib at any line.
This is an observational, non-interventional, single-country, multicenter, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic EGFR mutation-positive NSCLC who had been treated with Afatinib s at any line.
The study is carried out by hospital-based oncologists/pneumonologists specializing in lung cancer under real-world conditions of daily clinical practice. Investigators were selected through a documented and structured feasibility process which accounted for physicians' qualifications, previous participation and experience in similar clinical studies, recruitment potential, and retention capability. In addition, in order to represent variations in current real-world patterns of care, research sites were recruited from various geographic regions in Greece, also taking into consideration the regional setting and type of healthcare site/institution (publicly/privately owned, specialized oncology/pulmonology clinic, university clinic).
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 59 is below the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Hellenic Cooperative Oncology Group is the lead sponsor of 58 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This is a retrospective analysis of patients with histologically confirmed Non-small cell lung cancer and EGFR mutated, with progressive disease. Patients analysed in this study have been treated with Afatinib in any line. Patients have been treated in Hellenic Cooperative Oncology Group(HeCOG)- affiliated departments of oncology.
Exclusion Criteria:
-
Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC
Progression Free Survival
Progression Free Survival
Time frame: From Day 1 of treatment with Afatinib until disease progression, death from any cause or last follow-up, whichever occurs first, up to 12 months
Overall survival
Overall survival
Time frame: From Day 1 of treatment with Afatinib until death from any cause or last follow-up, up to 24 months
Second progression-free survival (PFS2)
Second progression-free survival (PFS2)
Time frame: From the initiation of next treatment following discontinuation of Afatinib to the date of progression, death or last contact, up to 6 months
Assessment of the safety profile of Afatinib
assessment of the safety profile of Afatinib
Time frame: In every cycle, every 28 days
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hellenic Cooperative Oncology Group